Isthmus Partners LLC Increases Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Isthmus Partners LLC lifted its position in Zoetis Inc. (NYSE:ZTS) by 1.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 68,648 shares of the company’s stock after purchasing an additional 760 shares during the quarter. Zoetis comprises about 1.6% of Isthmus Partners LLC’s holdings, making the stock its 26th biggest holding. Isthmus Partners LLC’s holdings in Zoetis were worth $13,412,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the company. Hantz Financial Services Inc. grew its holdings in shares of Zoetis by 4.4% in the third quarter. Hantz Financial Services Inc. now owns 141,299 shares of the company’s stock valued at $27,607,000 after purchasing an additional 5,938 shares during the period. Vinva Investment Management Ltd grew its holdings in shares of Zoetis by 8.2% in the third quarter. Vinva Investment Management Ltd now owns 19,456 shares of the company’s stock valued at $3,790,000 after purchasing an additional 1,467 shares during the period. Financial Counselors Inc. grew its holdings in shares of Zoetis by 5.8% in the third quarter. Financial Counselors Inc. now owns 155,696 shares of the company’s stock valued at $30,420,000 after purchasing an additional 8,526 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Zoetis by 5.3% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,896,106 shares of the company’s stock valued at $761,221,000 after purchasing an additional 194,542 shares during the period. Finally, Public Sector Pension Investment Board grew its holdings in shares of Zoetis by 947.3% in the third quarter. Public Sector Pension Investment Board now owns 180,981 shares of the company’s stock valued at $35,360,000 after purchasing an additional 163,700 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. Stifel Nicolaus upped their price objective on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, September 18th. BTIG Research increased their target price on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Argus raised shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. JPMorgan Chase & Co. increased their target price on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Finally, Piper Sandler increased their target price on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $221.44.

Zoetis Stock Up 0.6 %

Shares of ZTS opened at $176.74 on Friday. The stock has a market capitalization of $79.74 billion, a PE ratio of 33.22, a P/E/G ratio of 2.71 and a beta of 0.90. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. The company’s 50-day simple moving average is $184.18 and its 200-day simple moving average is $180.78.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.12. The business had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The business’s quarterly revenue was up 11.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.36 earnings per share. Analysts forecast that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be issued a $0.432 dividend. The ex-dividend date is Thursday, October 31st. This represents a $1.73 annualized dividend and a yield of 0.98%. Zoetis’s dividend payout ratio (DPR) is 32.52%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.